Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2014 from OUS - Metastasis - biology and therapy
13 publications found
Poly(sebacic anhydride) nanocapsules as carriers: effects of preparation parameters on properties and release of doxorubicin
J Microencapsul, 32 (2), 166-74
DOI 10.3109/02652048.2014.973073, PubMed 25323326
pH-responsive nano carriers for doxorubicin delivery
Pharm Res, 32 (4), 1249-63
DOI 10.1007/s11095-014-1530-0, PubMed 25288014
Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges
Protoplasma, 252 (3), 755-74
DOI 10.1007/s00709-014-0730-0, PubMed 25398648
In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts
J Magn Reson Imaging, 41 (3), 601-9
DOI 10.1002/jmri.24588, PubMed 24532410
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts
Breast Cancer Res, 16 (1), R5
DOI 10.1186/bcr3597, PubMed 24447408
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510
Patient-derived xenograft models: an emerging platform for translational cancer research
Cancer Discov, 4 (9), 998-1013
DOI 10.1158/2159-8290.CD-14-0001, PubMed 25185190
Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts
Acta Oncol, 53 (8), 1086-92
DOI 10.3109/0284186X.2014.934398, PubMed 25017377
Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery
J Colloid Interface Sci, 433, 76-85
DOI 10.1016/j.jcis.2014.07.013, PubMed 25112915
Associations between tumor vascularization assessed by in vivo DCE-MRI and the presence of disseminated tumor cells in bone marrow in breast cancer patients at the time of diagnosis
J Magn Reson Imaging, 40 (6), 1382-91
DOI 10.1002/jmri.24502, PubMed 24470360
Melanoma brain colonization involves the emergence of a brain-adaptive phenotype
Oncoscience, 1 (1), 82-94
DOI 10.18632/oncoscience.11, PubMed 25593989
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
J Enzyme Inhib Med Chem, 30 (5), 689-721
DOI 10.3109/14756366.2014.966704, PubMed 25347767
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568